Diagnostic Approach to Prolonged aPTT Due to Factor Deficiency

Initial Evaluation and Mixing Study

• The American Society of Hematology recommends performing a mixing study (1:1 mix of patient plasma with normal plasma) immediately and after 2-hour incubation to distinguish factor deficiency from inhibitor presence 1, 2
• Immediate correction of the aPTT with normal plasma indicates factor deficiency, while failure to correct suggests an inhibitor (lupus anticoagulant or factor inhibitor) 1, 2, 3
• A Rosner index <11% supports factor deficiency, as values ≥11% indicate inhibitor presence 4
• The International Society on Thrombosis and Haemostasis suggests that immediate correction does not completely exclude acquired hemophilia A, so if clinical bleeding is present, proceed with inhibitor workup regardless 1, 3

Specific Factor Assays and Interpretation

• The British Committee for Standards in Haematology recommends measuring Factor VIII activity level, as deficiency causes hemophilia A (congenital or acquired), von Willebrand disease 1, 3, 5
• An isolated low Factor VIII level suggests hemophilia A or von Willebrand disease 1, 3
• If all intrinsic factors appear decreased, this may be an in vitro artifact from inhibitor depleting Factor VIII in the substrate plasma; repeat assays at higher serial dilutions to attenuate this effect 1, 3, 5

Exclude Confounding Factors and Clinical Context

• The American College of Chest Physicians recommends ruling out heparin contamination by checking thrombin time or reviewing medication history 4
• Warfarin effect should be considered, and testing deferred until INR <1.5 or 1-2 weeks after discontinuation if INR is 1.5-3.0 4
• Lupus anticoagulant testing should be performed even when mixing study corrects, as both conditions can coexist 1, 3, 5
• Do not assume immediate mixing study correction excludes all inhibitors, and proceed with Factor VIII inhibitor testing (Bethesda assay) if clinical presentation suggests acquired hemophilia A with bleeding 1, 3
• Do not interpret low factor levels at face value if lupus anticoagulant is present, as this causes artifactual lowering through phospholipid inhibition in the assay; repeat at higher dilutions 1, 3, 5

Correction on aPTT Mixing Test: Inherited and Acquired Factor Deficiencies

Primary Causes of Correction

• Hemophilia A (Factor VIII deficiency) is the most common inherited cause, presenting with isolated low Factor VIII activity and immediate correction on mixing studies, as recommended by the American Society of Hematology 6
• Von Willebrand disease presents with low Factor VIII levels and corrects on mixing studies, according to the American Society of Hematology 6
• Patient stress, recent exercise, pregnancy, or inflammatory illness can falsely elevate Factor VIII and VWF levels, potentially masking mild deficiencies, as noted by the American Society of Hematology 6

Follow-Up Testing After Correction

• If Factor VIII is isolated and low, distinguish between hemophilia A and von Willebrand disease by measuring VWF:RCo and VWF:Ag, as suggested by the American Society of Hematology 6

Differential Diagnosis of Prolonged aPTT Without Bleeding

Primary Differential Categories

• Acquired hemophilia A may present without bleeding symptoms initially, making an isolated prolonged aPTT the only finding, and international guidelines emphasize that isolated prolonged aPTT should always be investigated further irrespective of clinical findings because bleeding can develop suddenly, according to the American Society of Hematology 7, 8
• Elderly patients and postpartum women are at highest risk for acquired hemophilia A, which can present with an isolated prolonged aPTT without bleeding symptoms, and require immediate investigation, including mixing study and specific factor assays 7, 9, 10

Medication-Related Causes

• Direct oral anticoagulants (DOACs), particularly dabigatran, can prolong aPTT, and should be considered in the differential diagnosis of prolonged aPTT without bleeding, as recommended by the American College of Cardiology 11

Critical Pitfalls to Avoid

• Never dismiss isolated prolonged aPTT without bleeding as benign until acquired hemophilia A is definitively excluded, as bleeding can develop suddenly with high mortality, and the American Society of Hematology recommends further investigation 7, 8

Prolonged aPTT Causes and Diagnostic Considerations

Primary Diagnostic Categories

• In COVID-19 patients, lupus anticoagulant positivity reaches 45%, with 20% showing prolonged aPTT due to these antibodies 12, 13
• Unfractionated heparin (UFH) prolongs aPTT through antithrombin III enhancement, inhibiting factors XIIa, IXa, XIa, and Xa 14
• Factor IX deficiency (hemophilia B) causes bleeding and corrects on mixing studies 15

Consumptive Coagulopathy and Heparin Resistance

• Critically ill patients, particularly those with COVID-19, may develop consumptive coagulopathy causing aPTT prolongation 12, 13
• Elevated fibrinogen and acute phase reactants (C-reactive protein) in inflammatory states create heparin resistance, requiring UFH doses exceeding 35,000 units/day to achieve therapeutic range 12, 13
• Hyperfibrinogenemia antagonizes heparin's anticoagulant effects through binding to heparin-binding proteins 12, 13

Preanalytical Interferences

• Sample collection and processing variables significantly influence aPTT measurements, particularly with UFH monitoring 12, 13

Isolated Prolonged Activated Partial Thromboplastin Time (APTT) Causes and Diagnostic Approach

Primary Diagnostic Categories

• Lupus anticoagulant is the most frequent cause of isolated APTT prolongation, occurring in up to 45% of certain populations, and this antiphospholipid antibody prolongs APTT through interference with phospholipid-dependent coagulation tests in vitro, but paradoxically increases thrombotic risk rather than bleeding risk, according to the National Comprehensive Cancer Network 16
• Critical pitfall: A prolonged APTT from lupus anticoagulant is NOT a contraindication to anticoagulation therapy—these patients actually require anticoagulation for thrombosis prevention if they meet criteria for antiphospholipid syndrome, as recommended by the National Comprehensive Cancer Network 16

Special Clinical Contexts

• In critically ill patients with hyperinflammation, elevated fibrinogen and Factor VIII can create heparin resistance, requiring UFH doses exceeding 35,000 units/day, and monitor UFH with anti-Xa assay rather than APTT in inflammatory states, as APTT becomes unreliable due to acute phase reactants, according to Anaesthesia 17

Interpretation of Normal PT in the Setting of Isolated Prolonged aPTT

Exclusion of Extrinsic and Common Pathway Factor Deficiencies

• A normal prothrombin time of 10.0 seconds in a patient who has an isolated prolonged activated partial thromboplastin time (aPTT) effectively rules out deficiencies of extrinsic and common pathway coagulation factors—including Factor VII, Factor X, Factor V, prothrombin, and fibrinogen—because these would be expected to prolong the PT when deficient. 18